(124 days)
The uMR Omega system is indicated for use as a magnetic device (MRDD) that produces sagittal. transverse, coronal, and oblique cross sectional images, and that display internal anatomical structure and/or function of the head, body and extremities.
These images and the physical parameters derived from the interpreted by a trained physician yield information that may assist the diagnosis. Contrast agents may be used depending on the region of interest of the scan.
The uMR Omega is a 3.0T superconducting magnetic resonance diagnostic device with a 75cm size patient bore. It consists of components such as magnet, RF power amplifier, RF coils, gradient power amplifier, gradient coils, patient table, spectrometer, computer, equipment cabinets, power distribution system, internal communication system, and vital signal module etc. The uMR Omega Magnetic Resonance Diagnostic Device is designed to conform to NEMA and DICOM standards.
This document is a 510(k) premarket notification for the uMR Omega Magnetic Resonance Diagnostic Device. It outlines modifications to a previously cleared device (K220332) and claims substantial equivalence to that predicate device. The information provided heavily focuses on technical characteristics and safety standards rather than detailed clinical performance studies with specific acceptance criteria related to diagnostic accuracy.
Therefore, many of the requested details, such as specific acceptance criteria for diagnostic performance, exact device performance metrics against those criteria, details of a test set for diagnostic accuracy (sample size, provenance, expert qualifications, adjudication method), human-in-the-loop studies (MRMC), or a standalone performance study in the context of diagnostic accuracy, are not explicitly present in the provided text.
The document primarily discusses technical specifications, safety, and the additions/modifications to the device. The "Performance Data" section mentions "Clinical performance evaluation" and "Performance evaluation report" for various sequences and imaging processing methods (4D Flow, MRE, CEST, T1rho, mPLD ASL, silica gel imaging). However, it does not provide the acceptance criteria for these evaluations or the results against such criteria in terms of diagnostic accuracy or clinical utility metrics. Instead, it concludes generally that "The test results demonstrated that the device performs as expected."
Based on the provided text, here's what can be extracted and what is missing:
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly state acceptance criteria for diagnostic performance in terms of sensitivity, specificity, accuracy, etc. for any specific medical condition. The reported performance is general compliance with technical standards and the device performing "as expected."
| Acceptance Criteria Category (Implied/General) | Stated Performance (General) | Specific Value/Threshold (If available) |
|---|---|---|
| Electrical Safety | Comply with ES 60601-1 | ES 60601-1 |
| EMC (Electromagnetic Compatibility) | Comply with IEC 60601-1-2 | IEC 60601-1-2 |
| SAR (Specific Absorption Rate) | Comply with IEC 60601-2-33 | IEC 60601-2-33 |
| dB/dt (Time Rate of Change of Magnetic Field) | Comply with IEC 60601-2-33 | IEC 60601-2-33 |
| Biocompatibility | Tested and demonstrated no cytotoxicity, irritation, and sensitization | ISO 10993-5, ISO 10993-10 (results imply compliance) |
| Surface Heating | NEMA MS 14 | NEMA MS 14 |
| SNR (Signal-to-Noise Ratio) | Compliance with standards acknowledged | MS 1-2008(R2020), MS 6-2008(R2014), MS 9-2008(R2020) (no specific values reported) |
| Image Uniformity | Compliance with standards acknowledged | MS 3-2008(R2020) (no specific values reported) |
| Positioning Error (with uVision) | $\leq \pm 5cm$ | $\leq \pm 5cm$ |
| Overall Device Performance | Performs as expected and is substantially equivalent to predicate | General statement, no specific metrics of diagnostic accuracy or clinical utility are provided. |
2. Sample size used for the test set and the data provenance
Not explicitly stated for diagnostic performance evaluations. The "Clinical performance evaluation" and "Performance evaluation report" are mentioned, but details on the patient cohort (sample size, retrospective/prospective, country of origin) are missing. These mentions are likely referring to technical performance characteristics rather than clinical diagnostic accuracy.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
Not explicitly stated. Given the nature of the submission (510(k) for a device with modifications, primarily focusing on technical specifications and safety standards), a detailed ground truth establishment process for diagnostic accuracy studies is not commonly part of this type of documentation unless new clinical claims or algorithms affecting diagnostic interpretation are being introduced and require such validation. The document states that images are "interpreted by a trained physician," but this is a general statement about usage, not about expert panel for ground truth.
4. Adjudication method for the test set
Not explicitly stated.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
No indication of an MRMC study. The document describes a Magnetic Resonance Diagnostic Device (MRI machine itself) and its embedded imaging processing methods, not an AI-assisted diagnostic tool that would typically undergo such a study.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
No indication of a standalone diagnostic algorithm performance study. The listed "imaging processing methods" (4D Flow Quantification, MRE, SNAP, CEST, T1Rho, FSP+) are features of the MRI system, and their performance is implied to be evaluated as part of the overall system's technical function and image quality, not as standalone diagnostic algorithms with their own "ground truth" performance metrics.
7. The type of ground truth used
Not explicitly stated for diagnostic accuracy. For the technical performance aspects, the "ground truth" would be measurements against established physical standards and phantom data to ensure image quality, signal integrity, and safety parameters meet specifications.
8. The sample size for the training set
Not applicable/Not mentioned. This document describes an MRI machine, not a machine learning or AI algorithm that would typically have a separate training set. The "imaging processing methods" are embedded features or techniques, not typically AI models trained on large datasets in the way common AI diagnostics are.
9. How the ground truth for the training set was established
Not applicable/Not mentioned. (See point 8).
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
May 23, 2023
Shanghai United Imaging Healthcare Co., Ltd. % Xin Gao Regulatory Affairs Specialist No.2258 Chengbei Road, Jiading District Shanghai, Shanghai 201807 China
Re: K230152
Trade/Device Name: uMR Omega Regulation Number: 21 CFR 892.1000 Regulation Name: Magnetic Resonance Diagnostic Device Regulatory Class: Class II Product Code: LNH Dated: April 24, 2023 Received: April 24, 2023
Dear Xin Gao:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
{1}------------------------------------------------
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
D.G.K.
Daniel M. Krainak, Ph.D. Assistant Director Magnetic Resonance and Nuclear Medicine Team DHT8C: Division of Radiological Imaging and Radiation Therapy Devices OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K230152
Device Name uMR Omega
Indications for Use (Describe)
The uMR Omega system is indicated for use as a magnetic device (MRDD) that produces sagittal. transverse, coronal, and oblique cross sectional images, and that display internal anatomical structure and/or function of the head, body and extremities.
These images and the physical parameters derived from the interpreted by a trained physician yield information that may assist the diagnosis. Contrast agents may be used depending on the region of interest of the scan.
| Type of Use (Select one or both, as applicable) |
|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) |
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
Image /page/3/Picture/1 description: The image shows the logo for United Imaging. The logo consists of the words "UNITED IMAGING" in bold, sans-serif font, stacked on top of each other. To the right of the words is a stylized "U" shape, which is also in bold. The color of the logo is a dark gray or blue.
510 (k) SUMMARY
1. Date of Prepared
April 24, 2023
2. Sponsor Identification
Shanghai United Imaging Healthcare Co., Ltd. No.2258 Chengbei Rd. Jiading District, 201807, Shanghai, China
Contact Person: Xin GAO Position: Regulatory Affairs Specialist Tel: +86-021-67076888-5386 Fax: +86-021-67076889 Email: xin.gao@united-imaging.com
3. Identification of Proposed Device(s)
Trade Name: uMR Omega Common Name: Magnetic Resonance Diagnostic Device Model: uMR Omega Product Code: LNH Regulation Number: 21 CFR 892.1000 Device Class: II
4. Identification of Predicate Devices(s)
Predicate Device 510(k) Number: K220332 Device Name: uMR Omega Regulation Number: 21 CFR 892.1000 Regulation Name: Magnetic Resonance Diagnostic Device Regulatory Class: II Product Code: LNH
5. Device Description
The uMR Omega is a 3.0T superconducting magnetic resonance diagnostic device with a 75cm size patient bore. It consists of components such as magnet, RF power amplifier, RF coils, gradient power amplifier, gradient coils, patient table, spectrometer, computer, equipment cabinets, power distribution system, internal communication system, and vital signal module etc. The uMR Omega Magnetic Resonance Diagnostic Device is designed to conform to NEMA and DICOM
{4}------------------------------------------------
Image /page/4/Picture/1 description: The image contains the logo for United Imaging. The logo consists of the words "UNITED IMAGING" in bold, sans-serif font, stacked on top of each other. To the right of the text is a stylized "U" shape, also in a dark color, with a vertical line running down the center, creating a unique design element.
standards.
uMR Omega has been previously cleared by FDA via K220332.
The modification performed on the uMR Omega (K220332) in this submission is due to the following changes that include:
- (1) Addition of the Radio Frequency Power Amplifier model: uXD2201.
- (2) Addition of Radio Frequency Coils: Tx/Rx Knee Coil -24 and SuperFlex Body Wide - 24.
- (3) Addition of VSM models: uVWMERP, uMVRX and mmw100.
- (4) Addition and modification of pulse sequences
- New sequences: gre_snap, gre_quick_4dncemra, gre_trass, epi_se_mre, gre_fq. a)
- b) Added Associated options for certain sequences: T1Rho, CEST, FSP+ (eT1, eGM), silica gel imaging, mPLD, whole heart coronary angiography imaging.
- Name change of pulse sequence: gre (old name: gre sp), gre fine (old name: c) gre_bssfp_fi), gre_quick (gre_quick_wfi merge to gre_quick), gre_quick (gre_bloustracking merge to gre_quick).
- (5) Addition of imaging processing methods: 4D Flow Quantification, Magnetic Resonance Elastography (MRE), SNAP, CEST, T1Rho, FSP+.
- (6) Addition of Dockable Patient Table.
- (7) Add the positioning workflow (uVision) with camera.
- (8) Addition of Resoundant Acoustic Driver System for Magnetic Resonance Elastography (MRE).
These modifications do not affect the intended use or alter the fundamental scientific technology of the device.
6. Intended Use
The uMR Omega system is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces sagittal, transverse, coronal, and oblique cross sectional images, and spectroscopic images, and that display internal anatomical structure and/or function of the head, body and extremities.
These images and the physical parameters derived from the images when interpreted by a trained physician yield information that may assist the diagnosis. Contrast agents may be used depending on the region of interest of the scan.
7. Technological Characteristic
The differences from the predicate device are discussed in the comparison table in this submission as below.
| ITEM | Proposed DeviceuMR Omega | Predicate DeviceuMR Omega (K220332) | Remark |
|---|---|---|---|
| General | |||
| 510(K) No. | K220332 | ||
| ITEM | Proposed DeviceuMR Omega | Predicate DeviceuMR Omega (K220332) | Remark |
| Product Code | LNH | LNH | Same |
| Regulation No. | 21 CFR 892.1000 | 21 CFR 892.1000 | Same |
| Class | II | II | Same |
| Indications For Use | The uMR Omega system isindicated for use as a magneticresonance diagnostic device(MRDD) that produces sagittal,transverse, coronal, and obliquecross sectional images, andspectroscopic images, and thatdisplay internal anatomicalstructure and/or function of thehead, body and extremities.These images and the physicalparameters derived from theimages when interpreted by atrained physician yieldinformation that may assist thediagnosis. Contrast agents maybe used depending on the regionof interest of the scan. | The uMR Omega system isindicated for use as a magneticresonance diagnostic device(MRDD) that produces sagittal,transverse, coronal, and obliquecross sectional images, andspectroscopic images, and thatdisplay internal anatomicalstructure and/or function of thehead, body and extremities.These images and the physicalparameters derived from theimages when interpreted by atrained physician yieldinformation that may assist thediagnosis. Contrast agents maybe used depending on the regionof interest of the scan. | Same |
| Magnet system | |||
| Field Strength | 3.0 Tesla | 3.0 Tesla | Same |
| Type of Magnet | Superconducting | Superconducting | Same |
| Patient-accessiblebore dimensions | 75cm | 75cm | Same |
| Type of Shielding | Actively shielded, OIStechnology | Actively shielded, OIStechnology | Same |
| MagnetHomogeneity | 2.30ppm @ 50cm DSV0.80ppm @ 45cm DSV0.38ppm @ 40cm DSV0.08ppm @ 30cm DSV0.02ppm @ 20cm DSV0.002ppm @ 10cm DSV | 2.30ppm @ 50cm DSV0.80ppm @ 45cm DSV0.38ppm @ 40cm DSV0.08ppm @ 30cm DSV0.02ppm @ 20cm DSV0.002ppm @ 10cm DSV | Same |
| Gradient system | |||
| Max gradientamplitude | 45mT/m | 45mT/m | Same |
| Max slew rate | 200T/m/s | 200T/m/s | Same |
| Shielding | active | active | Same |
| Cooling | water | water | Same |
| RF system | |||
| ITEM | Proposed DeviceuMR Omega | Predicate DeviceuMR Omega (K220332) | Remark |
| Resonantfrequencies | 128.23 MHz | 128.23 MHz | Same |
| Number of transmitchannels | 2 | 2 | Same |
| Number of receivechannels | Up to 96 | Up to 96 | Same |
| Amplifier peakpower per channel | 18 kW, 20 kW | 18 kW | Note 1 |
| RF Coils | |||
| Volume TransmitCoil | Yes | Yes | Same |
| Head & Neck Coil -24 | Yes | Yes | Same |
| Body Array Coil -12 | Yes | Yes | Same |
| Breast Coil - 10 | Yes | Yes | Same |
| Flex Coil Large - 8 | Yes | Yes | Same |
| Flex Coil Small - 8 | Yes | Yes | Same |
| Knee Coil - 12 | Yes | Yes | Same |
| Lower ExtremityCoil - 36 | Yes | Yes | Same |
| Shoulder Coil - 12 | Yes | Yes | Same |
| Small Loop Coil | Yes | Yes | Same |
| Spine Coil - 32 | Yes | Yes | Same |
| Wrist Coil - 12 | Yes | Yes | Same |
| Cardiac Coil - 24 | Yes | Yes | Same |
| TemporomandibularJoint Coil - 4 | Yes | Yes | Same |
| Foot & Ankle Coil -24 | Yes | Yes | Same |
| Head Coil - 32 | Yes | Yes | Same |
| Head Coil - 12 | Yes | Yes | Same |
| Carotid Coil - 8 | Yes | Yes | Same |
| Infant Coil - 24 | Yes | Yes | Same |
| Body Array Coil -24 | Yes | Yes | Same |
| Head & Neck Coil -48 | Yes | Yes | Same |
| Spine Coil - 48 | Yes | Yes | Same |
| Head Coil - 64 | Yes | Yes | Same |
| SuperFlex Body -24 | Yes | Yes | Same |
| ITEM | Proposed DeviceuMR Omega | Predicate DeviceuMR Omega (K220332) | Remark |
| SuperFlex Large -12 | Yes | Yes | Same |
| SuperFlex Small -12 | Yes | Yes | Same |
| Tx/Rx Knee Coil -24 | Yes | No | Note 2 |
| SuperFlex BodyWide - 24 | Yes | No | Note 3 |
| Dimensions | Patient Table:width 640mm, height 880mm,length 2620mmDockable Patient Table:width 826mm, height 880mm,length 2578mm | width 640mm, height 880mm,length 2620mm | Note 4 |
| Maximumsupported patientweight | Patient Table:310 kgDockable Patient Table:310kg | 310 kg | Same |
| Vital Signal Gating | Wireless UIH Gating Unit453564324621ECG module989803163121SpO2 module989803163111(alternative) | Wireless UIH Gating Unit453564324621ECG module989803163121SpO2 module989803163111(alternative) | Same |
| ECG, Rrespiration and pulsemoduleuVWMERPWireless gating trigger unituMVRX(alternative) | / | Note 5 | |
| Respiration module | / | Note 6 | |
| mmw100(optional) | / | ||
| Max View Angle | 75° | / | Note 7 |
| Positioning Error | $\leq \pm 5cm$ | / | Note 7 |
| Electrical Safety | Comply with ES 60601-1 | Comply with ES 60601-1 | Same |
| ITEM | Proposed DeviceuMR Omega | Predicate DeviceuMR Omega (K220332) | Remark |
| EMC | Comply with IEC 60601-1-2 | Comply with IEC 60601-1-2 | Same |
| Max SAR forTransmit Coil | Comply with IEC 60601-2-33 | Comply with IEC 60601-2-33 | Same |
| Max dB/dt | Comply with IEC 60601-2-33 | Comply with IEC 60601-2-33 | Same |
| Biocompatibility | Patient Contact Materials weretested and demonstrated nocytotoxicity (ISO 10993-5), noevidence for irritation andsensitization (ISO 10993-10). | Patient Contact Materials weretested and demonstrated nocytotoxicity (ISO 10993-5), noevidence for irritation andsensitization (ISO 10993-10). | Same |
| Surface Heating | NEMA MS 14 | NEMA MS 14 | Same |
Table 1 Comparison of Hardware configuration
{5}------------------------------------------------
Image /page/5/Picture/1 description: The image contains the logo for United Imaging. The words "UNITED" and "IMAGING" are stacked on top of each other in a bold, sans-serif font. To the right of the text is a stylized "U" symbol, which is composed of a vertical line and a horizontal line, with a curved bottom.
{6}------------------------------------------------
Image /page/6/Picture/1 description: The image shows the logo for United Imaging. The words "UNITED IMAGING" are stacked on top of each other in a bold, sans-serif font. To the right of the words is a stylized "U" shape, which is also in a bold font. The logo is simple and modern, and the colors are muted.
{7}------------------------------------------------
Image /page/7/Picture/1 description: The image contains the logo for United Imaging. The text "UNITED" is stacked on top of the text "IMAGING". To the right of the text is a stylized letter "U" that is dark blue. The logo is simple and modern.
{8}------------------------------------------------
Image /page/8/Picture/1 description: The image contains the logo for United Imaging. The logo consists of the words "UNITED IMAGING" in bold, sans-serif font, stacked on top of each other. To the right of the text is a stylized "U" symbol, which is also in a bold, sans-serif font. The symbol is a dark gray color, and the text is a slightly lighter shade of gray.
| Note 1 | This submission adds a new radio frequency power amplifier model (uXD2201), which increases theamplifier peak power. The increase of peak output power is to reserve power margin for the magneticresonance imaging system to better adapt to the scanning of patients with large loads, which is beneficialto the effectiveness of the system. |
|---|---|
| Note 2 | The intended use of Tx/Rx Knee Coil is essentially identical to previously cleared Knee Coil -12. The firstdifference is that the Tx/Rx Knee Coil is of a 16 Legs High-Pass Birdcage used for transmitter coil. Thesecond difference is the number of channels of the receiver coil. |
| Note 3 | The intended use of Super Flex Wide - 24 is essentially identical to previously cleared Body Array Coil -24. The differences are the material used on the surface of the coil. The flexible material is beneficial towrap the scanning parts. |
| Note 4 | This submission adds Dockable Patient Table to facilitate patient transfer. |
| Note 5 | Compared to the predicate device, the proposed device add an alternative VSM model (includeuVWMERP and uMVRX). The trigger method, principle, connection mode, installation position and otheraspects of this model are completely consistent with the original model. |
| Note 6 | Compared to the predicate device, the proposed device adds a respiratory gating mmw100 to monitorpatient respiration. Compared with contact respiratory gating, mmw100 eliminates the operation of patientbinding before scan, thus improving patient scan comfort. |
| Note 7 | This submission adds a new positioning method using uVision to automatically move the located positionto the isocenter of the magnet. This method reduces the steps of positioning and improves the previouscumbersome operation mode. |
| Table 2 provides the new application software features of the proposed device in |
software features of the proposed device comparison to the predicate device.
Table 2 Comparison of the new Application Software Features
| ITEM | ProposedDeviceuMR Omega | PredicateDeviceuMR Omega(K220332) | Remark |
|---|---|---|---|
| Image Processing Features | |||
| 4D Flow Quantification | Yes | No | 4D Flow Quantification is substantiallyequivalent to GRE and uses extra threedirection flow encoding gradients andrepeats several times acquisition, andthen uses specific imaging processing for |
{9}------------------------------------------------
Image /page/9/Picture/1 description: The image contains the logo for United Imaging. The logo consists of the words "UNITED IMAGING" stacked on top of each other in a sans-serif font. To the right of the text is a stylized "U" shape, which is made up of two vertical bars and a horizontal bar in the middle. The logo is simple and modern, and the use of a sans-serif font gives it a clean and professional look.
| 4D (3D space directions and 1D timedirection) flow quantification. | |||
|---|---|---|---|
| Magnetic ResonanceElastography (MRE) | Yes | No | Magnetic Resonance Elastography(MRE) is substantially equivalent toEPI_SE and uses extra motion encodinggradient to capture micro shear wavemotion induced by vibration device andspecific imaging processing for stiffnessquantification. |
| SNAP | Yes | No | SNAP is substantially equivalent to GREwith two TI acquisitions and usesspecific imaging processing to attainSimultaneous Non-contrast Angiographyand intraPlaque hemorrhage images. |
| CEST | Yes | No | CEST is substantially equivalent toFSE_MX and uses extra chemicalexchange saturation preparation pulsewith different resonance frequencies toattain Z-spectrum and final CEST image. |
| T1Rho | Yes | No | T1Rho is substantially equivalent to GREor FSE_MX and uses extra spin lockpreparation pulse to attain T1Rhoquantification mapping. |
| FSP+ | Yes | No | FSP+ is substantially equivalent to FSPand acquires one more TI images.According to two TI images, eT1 (T1Enhanced) and eGM (Gray MatterEnhanced) images can be attained byspecific image processing |
Based on the comparison and analysis above, the proposed device has same intended use, similar performance, equivalence safety and effeteness in hardware and software as the predicate device. The differences above between the proposed device and predicate device do not affect the intended use, technology characteristics, safety and effectiveness. And no issues are raised regarding to safety and effectiveness.
8. Performance Data
The following performance data according to FDA guidances and Recognized Consensus Standards were provided in support of the substantial equivalence determination.
- ES 60601-1 Medical electrical equipment Part 1: General requirements for basic A safety and essential performance
{10}------------------------------------------------
Image /page/10/Picture/1 description: The image contains the logo for United Imaging. The logo consists of the words "UNITED IMAGING" stacked on top of each other in a bold, sans-serif font. To the right of the text is a stylized symbol that resembles a shield or a stylized letter U. The symbol is divided vertically by a white line, creating a distinct visual element.
- A IEC 60601-1-2 Medical electrical equipment Part 1-2: General Requirements for basic safety and essential Performance
- A IEC 60601-2-33 Ed. 3.1:2013. Medical Electrical Equipment - Part 2-33: Particular Requirements For The Basic Safety And Essential Performance Of Magnetic Resonance Equipment For Medical Diagnostic
- A ISO 10993-5 Third Edition 2009-06-01, Biological Evaluation Of Medical Devices - Part 5: Tests For In Vitro Cytotoxicity
- A ISO 10993-10 Third Edition 2010-08-01, Biological Evaluation Of Medical Devices - Part 10: Tests For Irritation And Skin Sensitization
-
MS 1-2008(R2020), Determination of Signal-to-Noise Ratio (SNR) in Diagnostic Magnetic Resonance Images
- A MS 3-2008(R2020), Determination of Image Uniformity in Diagnostic Magnetic Resonance Images
- A MS 6-2008(R2014), Determination of Signal-to-Noise Ratio and Image Uniformity for Single-Channel Non-Volume Coils in Diagnostic MR Imaging
- A MS 9-2008(R2020), Standards Publication Characterization of Phased Array Coils for Diagnostic Magnetic Resonance Images
- A MS 14-2019, Characterization of Radiofrequency (RF) Coil Heating in Magnetic Resonance Imaging Systems
Non-clinical testing were conducted to verify the features described in this premarket submission.
- A Clinical performance evaluation
- A Performance evaluation report: 4D Flow (sequence: gre_fq); Magnetic
Resonance Elastography (sequence: epi se mre); CEST (sequence: fse mx);
T1rho (sequence: gre, fse mx); mPLD ASL (sequence: asl 3d); silica gel
imaging (sequence: fse, fse arms, fse ssh).
The test results demonstrated that the device performs as expected and thus, it is substantial equivalent to the predicate devices to which it has been compared.
9. Conclusion
In accordance with the Federal Food, Drug and Cosmetic Act, 21 CFR Part 807 and based on the information provided in this premarket notification, we conclude that uMR Omega Magnetic Resonance Diagnostic Device is substantially equivalent to the predicate device. It does not introduce new indications for use, and has the same technological characteristics and does not introduce new potential hazards or safety risks.
§ 892.1000 Magnetic resonance diagnostic device.
(a)
Identification. A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).(b)
Classification. Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.